215 related articles for article (PubMed ID: 32432675)
1. Differential Glucocorticoid-Dependent Regulation and Function of the ERRFI1 Gene in Triple-Negative Breast Cancer.
Mojica CAR; Ybañez WS; Olarte KCV; Poblete ABC; Bagamasbad PD
Endocrinology; 2020 Jul; 161(7):. PubMed ID: 32432675
[TBL] [Abstract][Full Text] [Related]
2. Krüppel-like factor 9 (KLF9) links hormone dysregulation and circadian disruption to breast cancer pathogenesis.
Ybañez WS; Bagamasbad PD
Cancer Cell Int; 2023 Feb; 23(1):33. PubMed ID: 36823570
[TBL] [Abstract][Full Text] [Related]
3. Significance of glucocorticoid signaling in triple-negative breast cancer patients: a newly revealed interaction with androgen signaling.
Kanai A; McNamara KM; Iwabuchi E; Miki Y; Onodera Y; Guestini F; Khalid F; Sagara Y; Ohi Y; Rai Y; Yamaguchi R; Tanaka M; Miyashita M; Ishida T; Sasano H
Breast Cancer Res Treat; 2020 Feb; 180(1):97-110. PubMed ID: 31989378
[TBL] [Abstract][Full Text] [Related]
4. YAP1-induced RBM24 promotes the tumorigenesis of triple-negative breast cancer through the β-catenin pathway.
Chen X; Lin X; Xia X; Xiang X
J Investig Med; 2024 Jun; 72(5):403-413. PubMed ID: 38441112
[TBL] [Abstract][Full Text] [Related]
5. WBP2 Downregulation Inhibits Proliferation by Blocking YAP Transcription and the EGFR/PI3K/Akt Signaling Pathway in Triple Negative Breast Cancer.
Song H; Wu T; Xie D; Li D; Hua K; Hu J; Fang L
Cell Physiol Biochem; 2018; 48(5):1968-1982. PubMed ID: 30092563
[TBL] [Abstract][Full Text] [Related]
6. PRKCQ promotes oncogenic growth and anoikis resistance of a subset of triple-negative breast cancer cells.
Byerly J; Halstead-Nussloch G; Ito K; Katsyv I; Irie HY
Breast Cancer Res; 2016 Sep; 18(1):95. PubMed ID: 27663795
[TBL] [Abstract][Full Text] [Related]
7. Induction of SGK1 via glucocorticoid-influenced clinical outcome of triple-negative breast cancer patients.
Zhang J; Miki Y; Iwabuchi E; Xu J; Kanai A; Sagara Y; Ohi Y; Rai Y; Yamaguchi R; Tanaka M; Ishida T; Suzuki T; Sasano H
Breast Cancer Res Treat; 2023 Aug; 200(3):323-335. PubMed ID: 37286891
[TBL] [Abstract][Full Text] [Related]
8. FOXM1 regulates expression of eukaryotic elongation factor 2 kinase and promotes proliferation, invasion and tumorgenesis of human triple negative breast cancer cells.
Hamurcu Z; Ashour A; Kahraman N; Ozpolat B
Oncotarget; 2016 Mar; 7(13):16619-35. PubMed ID: 26918606
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA 603 acts as a tumor suppressor and inhibits triple-negative breast cancer tumorigenesis by targeting elongation factor 2 kinase.
Bayraktar R; Pichler M; Kanlikilicer P; Ivan C; Bayraktar E; Kahraman N; Aslan B; Oguztuzun S; Ulasli M; Arslan A; Calin G; Lopez-Berestein G; Ozpolat B
Oncotarget; 2017 Feb; 8(7):11641-11658. PubMed ID: 28036267
[TBL] [Abstract][Full Text] [Related]
10. FOXM1 transcriptionally regulates expression of integrin β1 in triple-negative breast cancer.
Hamurcu Z; Kahraman N; Ashour A; Ozpolat B
Breast Cancer Res Treat; 2017 Jun; 163(3):485-493. PubMed ID: 28361350
[TBL] [Abstract][Full Text] [Related]
11. Suppression of Spry1 inhibits triple-negative breast cancer malignancy by decreasing EGF/EGFR mediated mesenchymal phenotype.
He Q; Jing H; Liaw L; Gower L; Vary C; Hua S; Yang X
Sci Rep; 2016 Mar; 6():23216. PubMed ID: 26976794
[TBL] [Abstract][Full Text] [Related]
12. Fatty acid binding protein 7 mediates linoleic acid-induced cell death in triple negative breast cancer cells by modulating 13-HODE.
Kwong SC; Abd Jamil AH; Rhodes A; Taib NA; Chung I
Biochimie; 2020 Dec; 179():23-31. PubMed ID: 32931863
[TBL] [Abstract][Full Text] [Related]
13. LncRNA WEE2-AS1 promotes proliferation and inhibits apoptosis in triple negative breast cancer cells via regulating miR-32-5p/TOB1 axis.
Wang R; Huang Z; Qian C; Wang M; Zheng Y; Jiang R; Yu C
Biochem Biophys Res Commun; 2020 Jun; 526(4):1005-1012. PubMed ID: 32307083
[TBL] [Abstract][Full Text] [Related]
14. The natural compound Jatrophone interferes with Wnt/β-catenin signaling and inhibits proliferation and EMT in human triple-negative breast cancer.
Fatima I; El-Ayachi I; Taotao L; Lillo MA; Krutilina RI; Seagroves TN; Radaszkiewicz TW; Hutnan M; Bryja V; Krum SA; Rivas F; Miranda-Carboni GA
PLoS One; 2017; 12(12):e0189864. PubMed ID: 29281678
[TBL] [Abstract][Full Text] [Related]
15. Growth hormone-releasing hormone induced transactivation of epidermal growth factor receptor in human triple-negative breast cancer cells.
Vacas E; Muñoz-Moreno L; Valenzuela PL; Prieto JC; Schally AV; Carmena MJ; Bajo AM
Peptides; 2016 Dec; 86():153-161. PubMed ID: 27816751
[TBL] [Abstract][Full Text] [Related]
16. Reverse engineering of triple-negative breast cancer cells for targeted treatment.
Bluemel L; von Wahlde MK; Tio J; Kiesel L; Bernemann C
Maturitas; 2018 Feb; 108():24-30. PubMed ID: 29290211
[TBL] [Abstract][Full Text] [Related]
17. Modulation of Mitochondrial ERβ Expression Inhibits Triple-Negative Breast Cancer Tumor Progression by Activating Mitochondrial Function.
Song IS; Jeong YJ; Jeong SH; Kim JE; Han J; Kim TH; Jang SW
Cell Physiol Biochem; 2019; 52(3):468-485. PubMed ID: 30873822
[TBL] [Abstract][Full Text] [Related]
18. Guanylate-binding protein-1 is a potential new therapeutic target for triple-negative breast cancer.
Quintero M; Adamoski D; Reis LMD; Ascenção CFR; Oliveira KRS; Gonçalves KA; Dias MM; Carazzolle MF; Dias SMG
BMC Cancer; 2017 Nov; 17(1):727. PubMed ID: 29115931
[TBL] [Abstract][Full Text] [Related]
19. Tryptophan hydroxylase 1 and 5-HT
Gautam J; Banskota S; Regmi SC; Ahn S; Jeon YH; Jeong H; Kim SJ; Nam TG; Jeong BS; Kim JA
Mol Cancer; 2016 Nov; 15(1):75. PubMed ID: 27871326
[TBL] [Abstract][Full Text] [Related]
20. MET is a potential target for use in combination therapy with EGFR inhibition in triple-negative/basal-like breast cancer.
Kim YJ; Choi JS; Seo J; Song JY; Lee SE; Kwon MJ; Kwon MJ; Kundu J; Jung K; Oh E; Shin YK; Choi YL
Int J Cancer; 2014 May; 134(10):2424-36. PubMed ID: 24615768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
